首页 | 本学科首页   官方微博 | 高级检索  
     


Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Affiliation:1. State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China;2. Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA;3. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea;4. Maria Sklodowska-Curie National Research Institute of Oncology, Department of Lung Cancer and Thoracic Tumours, Warsaw, Poland;5. Kanazawa University Hospital, Kanazawa, Japan;6. Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China;7. Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil;8. Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey;9. Merck & Co., Inc., Rahway, NJ, USA;10. Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA
Abstract:
Keywords:tissue tumor mutational burden  single-gene genetic alterations  pembrolizumab  locally advanced or metastatic non-small-cell lung cancer  biomarker
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号